Merck (MRK) Immuno-Oncology Offering Lacks Combo; Goldman Maintains Neutral

June 3, 2013 3:34 PM EDT Send to a Friend
Get Alerts MRK Hot Sheet
Price: $58.54 -0.71%

Rating Summary:
    9 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 38 | New: 13
Trade MRK Now!
Join SI Premium – FREE
Goldman Sachs today maintained a Neutral rating on Merck (NYSE: MRK) and raised its price target to $50.00 (from $45.00). Analyst Jami Rubin noted Merck had a strong single agent immuno-oncology drug but was missing out on "combo potential."

"While we are encouraged by lambro, we believe that combo therapies may take the majority share of the immuno-oncology market. We have not seen anything in MRK's portfolio to date for combinations (although there may be earlier stage assets). This compares to ristol-Myers Squibb (NYSE: BMY) that has a large portfolio of immuno-oncology agents to use in combination, Rogers Corporation (NYSE: ROG) that has a portfolio of target therapies for combination, and even AstraZeneca (NYSE: AZN) while behind the other competitors also has potential for combination therapies," said Rubin.

For an analyst ratings summary and ratings history on Merck (NYSE: MRK) click here. For more ratings news on Merck click here.

Shares of Merck closed at $46.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Goldman Sachs

Add Your Comment